BioNTech SE

NASDAQ:BNTX

Biotechnology

Healthcare
$83.26 -1.52%

-$1.41 today

Market cap
$20.64B
Beta
1.32
P/E (TTM)
-16.2
EPS (TTM)
-$4.93
52W Low $79.52High $124.00

Volume 1.24M

Average 1.11M

BNTX Interest Expense

Cost of servicing the company's debt during the period.

BioNTech SENASDAQ: BNTX

Interest Expense · Q2 FY2026 · quarter ended Jun 2026

Interest expense growth accelerates

Q2 FY2026 interest expense of €7.9M rose 140.0% year over year, ahead of the +27.7% change in trailing-twelve-month interest expense. Sequentially, it rose 94.3% from the prior quarter. Over 3 fiscal years it compounded at -4.8% a year.

Context

  • Interest expense amounted to 0.5% of revenue in FY2025, unchanged from a year earlier.
  • Interest expense increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +140.0% holds above the trailing-twelve-month pace of +27.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
€7.9M+94.3% QoQ
Last fiscal yearDec 2025
€13.64M+3.6% YoY
LTMJun 2026
€18.8M+27.7% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+140.0%——
1 year+3.6%——
3-year CAGR-4.8%——
5-year CAGR——
10-year CAGR——

Interest Expense history

EUR · from the income statement

Latest · FY2025
13.64M EUR
Year-over-year change
+3.6%
4-year CAGR
+24.8%

Interest Expense vs competitors

How BNTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +27.7% is the 3rd highest of 8, against a peer median of -5.0%.
  • Interest expense amounts to 0.7% of revenue for BNTX, versus a peer median of 4.1%.
BNTX Competitors
Interest Expense for BNTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GMABGenmab A/SLTM Jun 2026$269.28M USD—+42.7%6.5%
IBRXImmunityBio, Inc.LTM Sep 2026$87.69M USD-12.5%+33.6%48.0%
TGTXTG Therapeutics, Inc.LTM Sep 2026$46.59M USD+70.9%+37.9%5.2%
XNCRXencor, Inc.LTM Jun 2026$27.07M USD-47.6%—25.8%
BNTXBioNTech SELTM Jun 2026€18.8M EUR+27.7%-4.8%0.7%
MGNXMacroGenics, Inc.LTM Mar 2026$13.31M USD+13616.5%—8.5%
IMCRImmunocore Holdings plcLTM Mar 2026$11.49M USD-34.5%+31.0%3.0%
INCYIncyte CorporationLTM Jun 2026$2.32M USD-5.0%-3.1%0.0%
IMTXImmatics N.V.LTM Mar 2026€909K EUR-3.5%-3.0%2.4%
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$0 USD——0.0%
CGENCompugen Ltd.LTM Mar 2026$0 USD——0.0%
Peer median (excluding BNTX) —-5.0%+32.3%4.1%

Competitors are the stored peer set for BNTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue18.98B17.31B3.82B2.75B2.76B
Cost of Revenue2.91B3B599.8M541.3M616.47M
Gross Profit16.07B14.32B3.22B2.21B2.14B
Gross Margin84.7%82.7%84.3%80.3%77.6%
Research & Development949.2M1.54B1.78B2.25B2.02B
Selling, General & Admin327.2M541.2M557.7M599M698.2M
Operating Expenses781.4M1.67B2.53B3.52B2.76B
Depreciation & Amortization75.2M123.3M183.4M298M367.69M
EBITDA15B13.1B1.38B(367.1M)(628M)
EBITDA Margin79.1%75.7%36.1%-13.3%-22.8%
Operating Income15.28B12.64B690.4M(1.31B)(623.87M)
Operating Margin80.5%73.0%18.1%-47.8%-22.6%
Interest Income1.56M47.37M351.31M0252.24M
Interest Expense5.63M15.82M7.76M13.16M13.64M
Other Income / Expenses(237.4M)311.4M495.7M636.6M(385.46M)
Income Before Tax15.05B12.95B1.19B(677.7M)(1.01B)
Pre-Tax Margin79.3%74.8%31.1%-24.6%-36.6%
Income Tax Expense4.75B3.52B255.8M(12.4M)81.93M
Net Income10.29B9.43B930.3M(665.3M)(1.09B)
Net Margin54.2%54.5%24.4%-24.2%-39.6%
EPS (Basic)43.8738.083.87(2.77)(4.51)
EPS (Diluted)41.2137.093.83(2.77)(4.51)
Weighted Avg Shares244M243.3M240.6M240.4M241.7M
Weighted Avg Shares (Diluted)259.7M249.8M242.7M240.4M241.7M

BioNTech SE

NASDAQ:BNTX

Intrinsic Alpha fair value

Locked

Current Price

$83.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.